Tipifarnib in Treating Young Patients With Refractory Leukemia
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary
for cancer cell growth.
PURPOSE: Phase I trial to study the effectiveness of tipifarnib in treating young patients
who have refractory leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)
Collaborators:
Children's Oncology Group National Cancer Institute (NCI)